Interferon treatment in patients with hypereosinophilia

Current Drug Targets

Volumn 12, Issue 3, 2011, Pages 429-432

  Bjerrum, Ole Weis ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Classification; Eosinophilia; Interferon; Review; Treatment

Indexed keywords

ALPHA INTERFERON; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DASATINIB; ETOPOSIDE; GLUCOCORTICOID; HYDROXYUREA; IMATINIB; INTERLEUKIN 5 ANTIBODY; NILOTINIB; PEGINTERFERON ALPHA2B; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANOREXIA; ARTICLE; CYTOKINE RELEASE; DEPRESSION; DRUG EFFICACY; DRUG TREATMENT FAILURE; EOSINOPHIL; EOSINOPHILIA; FATIGUE; FLU LIKE SYNDROME; HEMATOLOGICAL PARAMETERS; HUMAN; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; MONOTHERAPY; MUSCULOSKELETAL DISEASE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SKIN TOXICITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 79551623608     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011794815211     Document Type: Article

References (29)

1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1-27.
2. Gotlib J, Cools J, Malone JM, Schrier SL, Gililand DJ, Coutré SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879-91.
3. Gotlib J, Cross NCP, Gilliland DG. Eosinophilic disorders: molecular pathogenesis, new classification and modern therapy. Best Practice Res Clin Haematol 2006; 19: 535-69.
4. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006; 133: 468-92.
5. Vardiman JW, Porwit A, Brunning RD, et al. In: WHO classification of tumours of haematopoietic and lymphoid tissues; Swerdlow SH, Campo E, Harris NL, et al., Eds. Lyon: IARC 2008; pp. 18-30.
6. Bain BJ, Gilliland DG, Vardiman JW, Horny H-P. Chronic eosinophilic leukaemia, not otherwise specified. Ibid; pp 51-53.
7. Bain BJ, Gilliland DG, Horny H-P, Vardiman JW Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Ibid; pp. 68-73.
8. Kalac M, Quintás-Cardama A, Vrhovac R, Kantarjia H, Verstovsek S. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer 2007; 110: 955-64.
9. Kilon AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117: 1292-302.
10. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004; 104: 1931-9.
11. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005; 114: 26-40.
12. Flaum MA, Schooley RT, Fauci AS, Grainick HR. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Haematologic manifestations. Blood 1981; 58: 1012-20.
13. Schooley RT, Flaum MA, Grainick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood 1981; 58: 1021-6.
14. Alderbert D, Lamkhioued B, Desaint C, et al. Eosinophils express a functional receptor for interferon α: inhibitory role of interferon α on the release of mediators. Blood 1996; 87: 2354-60.
15. Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-α2b therapy in BCR-ABL-negative myeloproliferative disorders. Cancer 2007; 110: 2012-8.
16. Murphy PT, Fenelly DF, Stuart M, O'Donnel JR. Alpha-interferonin a case of hypereosinophilic syndrome. Br J Haematol 1990; 75: 619-20.
17. Zielinski RM, Lawrence WD. Interferon-α for the hypereosinophilic syndrome. Ann Intern Med 1990; 113: 716-8.
18. Talpaz M, Kanjarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigations of human alpha interferon in chronic myeloid leukemia. Blood 1987; 69: 1280-8.
19. Coutant G, Biétry O, Prin L, et al. Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases. Ann Med Interne (Paris) 1993; 144: 243-50.
20. Butterfield JH, Gleich GJ. Interferon-α treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994; 121: 648-53.
21. Certelli S, Capochiani E, Petrini M. Interferon-α in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Haematol 1998; 77: 161-4.
22. Bockenstedt PL, Santinga JT, Bolling SF. Alpha-interferon treatment for idiopathic hypereosinophilic syndrome. Am J Hematol 1994; 45: 248-51.
23. Malbrain ML, van der Bergh H, Zachée P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol 1996; 92: 176-83.
24. Yamada O, Kitahara K, Imamura K, Ozasa H, Okada M, Mizoguchi H. Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique (3;9;5) translocation. Am J Haematol 1998; 58: 137-41.
25. Nassar GM, Pedro P, Remmers RE, Mohanty LB, Smith W. Reverisble renal failure in a patient with the hypereosinophilia syndrome during therapy with alpha interferon. Am J Kidney Dis 1998; 31: 121-6.
26. Baretta L, Afeltra A, Delfino M, de Castro S, Giorgino F, Filippo-Fanelli F. Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy. Angiology 2002; 53: 465-70.
27. Kanthawatana S, Irani AM, Schwartz LB. Recombinant interferonaplha (IFNα) and pregnancy in a patient with hypereosinophilic syndrome. J Allergy Clin Immunol 1998; 101: S20 (abstract 88).
28. Schandené L, Roufosse F, de Lavarelle A, et al. Interferon α prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood 2000; 96: 4285-92.
29. Hansen PB, Johnsen HE, Hippe E. Hypereosinophilic syndrome treated with α-interferon and granulocyte colony-stimulating factor but complicated by nephrotoxicity. Am J Haematol 1993; 43: 66-8.